NO20033912L - Leporipox-baserte vektorvaksiner - Google Patents

Leporipox-baserte vektorvaksiner

Info

Publication number
NO20033912L
NO20033912L NO20033912A NO20033912A NO20033912L NO 20033912 L NO20033912 L NO 20033912L NO 20033912 A NO20033912 A NO 20033912A NO 20033912 A NO20033912 A NO 20033912A NO 20033912 L NO20033912 L NO 20033912L
Authority
NO
Norway
Prior art keywords
virus
lepori
exogenous dna
host
recombinant leporipox
Prior art date
Application number
NO20033912A
Other languages
English (en)
Other versions
NO20033912D0 (no
NO331305B1 (no
Inventor
Norman Spibey
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20033912D0 publication Critical patent/NO20033912D0/no
Publication of NO20033912L publication Critical patent/NO20033912L/no
Publication of NO331305B1 publication Critical patent/NO331305B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033912A 2001-03-08 2003-09-04 Levende rekombinant leporipox-virus, dets anvendelse, samt vaksine omfattende viruset NO331305B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200869 2001-03-08
PCT/EP2002/002858 WO2002072852A2 (en) 2001-03-08 2002-03-07 Leporipox-based vector vaccines

Publications (3)

Publication Number Publication Date
NO20033912D0 NO20033912D0 (no) 2003-09-04
NO20033912L true NO20033912L (no) 2003-10-22
NO331305B1 NO331305B1 (no) 2011-11-21

Family

ID=8179978

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033912A NO331305B1 (no) 2001-03-08 2003-09-04 Levende rekombinant leporipox-virus, dets anvendelse, samt vaksine omfattende viruset

Country Status (17)

Country Link
US (1) US6942864B2 (no)
EP (1) EP1370668B1 (no)
JP (1) JP4037273B2 (no)
CN (1) CN1258596C (no)
AT (1) ATE318321T1 (no)
AU (1) AU2002304856B2 (no)
BR (1) BR0207761A (no)
CA (1) CA2439872C (no)
DE (1) DE60209345T2 (no)
DK (1) DK1370668T3 (no)
ES (1) ES2258628T3 (no)
MX (1) MXPA03007862A (no)
NO (1) NO331305B1 (no)
NZ (1) NZ527940A (no)
PT (1) PT1370668E (no)
WO (1) WO2002072852A2 (no)
ZA (1) ZA200306607B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572893A (en) * 2006-06-01 2011-06-30 Robarts Res Inst Myxoma virus mutants for cancer treatment
KR100831536B1 (ko) * 2007-01-19 2008-05-22 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 풀 브릿지 드라이버
KR100831537B1 (ko) * 2007-01-19 2008-05-22 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 하프 브릿지 드라이버
FR2925067B1 (fr) * 2007-12-18 2010-01-15 Agronomique Inst Nat Rech Vecteurs vaccinaux derives de leporipoxvirus
WO2021202971A1 (en) * 2020-04-02 2021-10-07 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 vaccine based on the myxoma virus platform
CN111904981A (zh) * 2020-09-07 2020-11-10 威世药业（如皋）有限公司 一种痘苗病毒致炎兔皮生产方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
AU2347692A (en) 1991-07-09 1993-02-11 Cornell Research Foundation Inc. Recombinant viral vaccine
TW377373B (en) 1993-09-22 1999-12-21 Wyeth Corp Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
FR2736358B1 (fr) 1995-07-05 1997-09-26 Agronomique Inst Nat Rech Virus myxomateux recombinant
AU4266597A (en) * 1996-09-11 1998-04-14 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US6127172A (en) * 1998-05-29 2000-10-03 University Of Florida Materials and methods for delivery and expression of heterologous DNA in vertebrate cells
ES2153284B1 (es) * 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
US6294176B1 (en) * 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species

Also Published As

Publication number Publication date
CA2439872C (en) 2009-12-15
CN1258596C (zh) 2006-06-07
DE60209345T2 (de) 2006-08-03
CA2439872A1 (en) 2002-09-19
EP1370668A2 (en) 2003-12-17
BR0207761A (pt) 2006-01-31
MXPA03007862A (es) 2004-05-24
NO20033912D0 (no) 2003-09-04
EP1370668B1 (en) 2006-02-22
US6942864B2 (en) 2005-09-13
WO2002072852A3 (en) 2002-12-27
US20040137599A1 (en) 2004-07-15
AU2002304856B2 (en) 2006-08-24
JP2004528833A (ja) 2004-09-24
JP4037273B2 (ja) 2008-01-23
NZ527940A (en) 2005-01-28
ES2258628T3 (es) 2006-09-01
WO2002072852A2 (en) 2002-09-19
DE60209345D1 (de) 2006-04-27
DK1370668T3 (da) 2006-06-06
NO331305B1 (no) 2011-11-21
CN1527883A (zh) 2004-09-08
ZA200306607B (en) 2005-02-23
ATE318321T1 (de) 2006-03-15
PT1370668E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
EA200900180A1 (ru) Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном
ATE447967T1 (de) Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
FI931309A (fi) Viralt bristfaelligt vaccin, som har producerats med en transkomplementerande cellinie
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
MXPA05009580A (es) Vacuna contra el virus de la influenza.
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
NZ627888A (en) Materials and methods for respiratory disease control in canines
DE50206472D1 (de) Attenuierte lebendimpfstoffe
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
ES2608627T5 (es) Uso de un poxvirus modificado para inducción rápida de inmunidad frente a un poxvirus u otros agentes infecciosos
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
Hajam et al. Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen
DK1370668T3 (da) Leporipox-baserede vektorvacciner
TW200734463A (en) Marked bovine viral diarrhea virus vaccines
PH12018502460A1 (en) Arthrogenic alphavirus vaccine
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
CR11537A (es) Vacuna
WO2006113927A3 (en) Immunogenic vaccinia peptides and methods of using same
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees